Cargando…
Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
BACKGROUND: p-Boronophenylalanine ((10)BPA) is a powerful (10)B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of (10)BPA must be administered over a few hours. Here, we report BNCT efficacy after rapid, ultralow-dose administration of either tumor v...
Autores principales: | Yoneyama, Tohru, Hatakeyama, Shingo, Sutoh-Yoneyama, Mihoko, Yoshiya, Taku, Uemura, Tsuyoshi, Ishizu, Takehiro, Suzuki, Minoru, Hachinohe, Shingo, Ishiyama, Shintaro, Nonaka, Motohiro, Fukuda, Michiko N., Ohyama, Chikara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809749/ https://www.ncbi.nlm.nih.gov/pubmed/33446132 http://dx.doi.org/10.1186/s12885-020-07760-x |
Ejemplares similares
-
Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
por: Yoneyama, Tohru, et al.
Publicado: (2021) -
Renal metastasis of ovarian granulosa cell tumor
por: Togashi, Kyo, et al.
Publicado: (2022) -
Recent progress and perspectives on prostate cancer biomarkers
por: Hatakeyama, Shingo, et al.
Publicado: (2016) -
Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries
por: Konishi, Sakae, et al.
Publicado: (2021) -
Narrative review of urinary glycan biomarkers in prostate cancer
por: Hatakeyama, Shingo, et al.
Publicado: (2021)